LISBON – Conventional liver function tests may miss a diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes, according to prospective study findings.
Data from the NAFLD substudy of the ongoing Edinburgh Type 2 Diabetes Study (ET2DS) found that although hyaluronic acid (HA) may be a reasonably good indicator of whether liver fibrosis was absent, standard enzyme tests missed a significant proportion of fibrosis cases.
“The literature that we have is biased by the fact that when researchers have looked at more advanced liver disease, it's been in patients who have already earned themselves a liver biopsy for whatever reason,” Dr. Rachel Williamson said in an interview at the meeting “So what we add by this study is that this is an unselected population of patients who are essentially otherwise potentially well, from a liver point of view,” said Dr. Williamson of the Western General Hospital in Edinburgh.
Liver assessment was done in 939 of 1,000 individuals aged 60-75 years who were randomly selected from the Lothian Diabetes Register. Mcan age was 69 years, 52% were women, and 98% were white. Mean body mass index was 31.3 kg/m
All patients in the liver cohort underwent abdominal ultrasound, standard liver function tests (LFTs), detailed screening of secondary causes of liver disease, HA level, platelet count, and alpha-fetoprotein measurements. Because HA is found in high concentrations in the synovial joints, patients' history of joint disease was obtained.
“The prevalence of NAFLD in our population was 42%,” which is lower than the 70%-80% seen in some studies, Dr. Williamson said.
The quest to find reliable, noninvasive markers for advanced liver disease led Dr. Williamson and colleagues to examine the relationship between HA and the prevalence of hepatic fibrosis, portal hypertension, and hepatocellular carcinoma (HCC). Another noninvasive marker, the ratio of the platelet count to spleen size, was also used, and the usefulness of LFTs, alanine aminotransferase, aspartate aminotransferase, bilirubin, and gamma-glutamyltransferase were assessed.
An HA level greater than 50 ng/mL has been linked to liver fibrosis, with a higher cut-off of 100 ng/mL deemed to be more predictive of advanced liver disease. Using the lower threshold, 45% of the cohort had high HA levels, which could have been due to liver fibrosis in 24%. In all, 6% of the study population had HA in excess of 100 ng/mL. “We concluded that this 6% almost certainly had liver fibrosis,” Dr. Williamson said.
The prevalence of portal hypertension, cirrhosis and HCC in the entire cohort was 1.1%, 0.4%, and 0.2%, respectively. Figures were slightly lower in patients who had a no secondary cause of liver disease (0.6%, 0.2%, and 0.3%).
Although mean levels of ALT, AST and GGT were highest in patients with liver cirrhosis, compared with those with raised HA (more than 50 ng/mL or more than 100 ng/mL) and no arthritis, steatosis, or normal liver scan, these levels remained within normal limits.
The positive predictive values of ALT and GGT above normal for predicting fibrosis were low (26% and 29%, respectively). The respective negative predictive values were 75% and 75%.
“The use of conventional liver function tests to screen for liver disease missed a significant proportion of cases of fibrosis predicted by raised HA levels, Dr. Williams concluded.
The ET2DS study is funded by Pfizer. Dr. Williamson had no disclosures.